M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

Phase 2

Terminated

Conditions: Acute Lymphoblastic Leukemia in Remission
B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Biological: Inotuzumab Ozogamicin
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Mercaptopurine
Drug: Methotrexate
Biological: Ofatumumab
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2018-04-04

Last Posted Date: 2024-07-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT03488225

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

Phase 2

Completed

Conditions: Other Infectious Diseases

Interventions: Drug: Cefepime
Drug: Ceftolozane
Other: Laboratory Biomarker Analysis
Drug: Tazobactam
Drug: Meropenem
Drug: Piperacillin-Tazobactam

First Posted Date: 2018-04-03

Last Posted Date: 2022-03-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT03485950

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

Early Phase 1

Completed

Conditions: Bladder Urothelial Carcinoma
Clear Cell Renal Cell Carcinoma
Malignant Urinary System Neoplasm
Metastatic Kidney Carcinoma
Stage IV Renal Cell Cancer AJCC V8

Interventions: Procedure: Biopsy
Biological: Daratumumab
Other: Laboratory Biomarker Analysis
Procedure: Metastasectomy
Procedure: Nephrectomy

First Posted Date: 2018-03-22

Last Posted Date: 2025-01-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 17

Registration Number: NCT03473730

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Phase 1

Recruiting

Conditions: Hematopoietic and Lymphoid System Neoplasm
Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Recurrent Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Drug: Ivosidenib
Drug: Venetoclax

First Posted Date: 2018-03-20

Last Posted Date: 2025-04-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 96

Registration Number: NCT03471260

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)

Phase 2

Completed

Conditions: Oral Pain
Stomatitis
Malignant Neoplasm

Interventions: Other: Best Practice
Drug: Methylene Blue

First Posted Date: 2018-03-19

Last Posted Date: 2023-04-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 69

Registration Number: NCT03469284

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions

Recruiting

Conditions: Pleural Neoplasm

Interventions: Drug: Doxycycline
Device: Indwelling Catheter
Procedure: Quality-of-Life Assessment
Other: Survey Administration
Other: Questionnaire Administration

First Posted Date: 2018-03-14

Last Posted Date: 2025-04-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 208

Registration Number: NCT03465774

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)

Recruiting

Conditions: Pancreatic Cancer
Diabetes Mellitus Type 3c
Chronic Pancreatitis

Interventions: Other: Data Management and Monitoring

First Posted Date: 2018-03-09

Last Posted Date: 2025-03-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 775

Registration Number: NCT03460769

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

Not Applicable

Recruiting

Conditions: Brain Lesion

Interventions: Procedure: Advanced Magnetic Resonance Imaging Scan
Procedure: Standard of Care Brain Biopsy and Tumor Removal

First Posted Date: 2018-03-08

Last Posted Date: 2025-03-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT03458676

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Text Messages in Preventing Tobacco Use in Young Adults

Not Applicable

Completed

Conditions: Healthy Subject

Interventions: Other: Computer-Assisted Intervention
Behavioral: Focus Group
Other: Informational Intervention
Other: Survey Administration

First Posted Date: 2018-03-07

Last Posted Date: 2021-02-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 781

Registration Number: NCT03457480

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

Phase 1

Completed

Conditions: Human Papillomavirus-Related Cervical Squamous Cell Carcinoma
Metastatic Vulvar Carcinoma
Recurrent Cervical Adenocarcinoma
Recurrent Vaginal Carcinoma
Stage IV Cervical Cancer AJCC v8
Recurrent Cervical Carcinoma
Recurrent Vulvar Carcinoma
Stage IIIA Cervical Cancer AJCC v8
Stage IIIA Vulvar Cancer AJCC v8
Stage IIIB Cervical Cancer AJCC v8

Interventions: Biological: Durvalumab
Other: Laboratory Biomarker Analysis
Radiation: Stereotactic Radiosurgery
Biological: Tremelimumab

First Posted Date: 2018-03-02

Last Posted Date: 2023-09-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT03452332

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy